

# RAYMED LABS LIMITED

CIN: L24111UP1992PLC014240

Reg. off.-103 Emperor 1, Supertech Emerald Court, Sector 93A Noida,  
UP – 201304, Website- [www.raymedlab.com](http://www.raymedlab.com)

E-mail- [raymedlabs@rediffmail.com](mailto:raymedlabs@rediffmail.com), Phone no. - 0120-2426900, 9412700300

---

Date: 02.08.2023

The Head- Listing Compliance  
**BSE Limited**  
Phiroze Jeejeebhoy Towers  
Dalal Street  
Mumbai-400001

**Scrip Code: 531207**

**Sub: Outcome of Board Meeting pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

Dear Sir(s),

We would like to inform that the Board of Directors in their meeting held today, i.e. **Wednesday, 02<sup>nd</sup> day of August, 2023** (commenced at **03:30 P.M.** and concluded at **04:15 P.M.**), has inter alia approved and passed the following resolutions:

1. Consideration and Approval of the **Unaudited Standalone Financial Results** as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the quarter ended 30<sup>th</sup> June, 2023. **(Copy Enclosed)**
2. The Board considered and took on record, the **Limited Review Report** on Financial Results for the quarter ended 30<sup>th</sup> June, 2023 as placed by the Statutory Auditor of the Company. **(Copy Enclosed).**

Kindly take the above information on your records.

Thanking you,

**For Raymed Labs Limited**

**Ajai Goyal**  
**Whole Time Director**  
**DIN: 02636418**

**Place: Noida**



**LIMITED REVIEW REPORT ON UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE  
QUARTER ENDED ON 30<sup>TH</sup> JUNE, 2023**

**To**

**The Board of Directors**

**Raymed Labs Limited**

103 Emperor 1, Supertech Emerald Court,

Sector 93A, Noida - 201304

1. We have reviewed the accompanying statement of unaudited financial results ("The Statement") of Raymed Labs Limited ("The Company") for the period ended on 30<sup>th</sup> June, 2023, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016.
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and an analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.



# A. KAY. MEHRA & CO.

C H A R T E R E D A C C O U N T A N T S

2470 (BASEMENT), HUDSON LINE,  
G.T.B. NAGAR, DELHI-110009  
NEAR GTB NAGAR METRO STATION,  
Ph. No.: 011- 42461274, 9891295255  
E- Mail: akmca1969@gmail.com  
Website: www.akmca.in

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For A. Kay. Mehra & Co.**  
**Chartered Accountants**  
**FRN: (050004C)**

*Deepak Suneja*

**CA Deepak Suneja**  
**Membership No- 501957**



**UDIN: 23501957BGVOSU4709**

**Date: August 02, 2023**

**Place: Noida**

**Raymed Labs Limited**  
**Regd. Office: 103 Emperor 1, Supertech Emerald Court, Sector 93A, Noida - 201304,**  
**Uttar Pradesh, CIN: L24111UP1992PLC014240**  
**E-Mail: raymedlabs@rediffmail.com, Website: www.raymedlab.com,**  
**Tel: 0120-2426900, 9412700300**

**Statement of Standalone Unaudited Financial Results for the Quarter ended June 30, 2023**

Particulars	Amt. (In Lacs)			
	Quarter Ended			Year Ended
	30th June, 2023	31st March, 2023	30th June, 2022	31st March, 2023
	(Unaudited)	(Audited)	(Unaudited)	(Audited)
<b>I. Revenue from Operations</b>	0.00	0.00	0.00	0.00
<b>II. Other Income</b>	0.00	2.06	0.00	2.06
<b>III. Total Income (I +II)</b>	<b>0.00</b>	<b>2.06</b>	<b>0.00</b>	<b>2.06</b>
<b>IV. Expenses</b>				
Cost of Material Consumed	0.00	0.00	0.00	0.00
Purchases of Stock-in-trade	0.00	0.00	0.00	0.00
Changes in inventories of finished goods, Work-in-progress and stock-in-trade	0.00	0.00	0.00	0.00
Employee Benefits Expenses	0.90	0.90	1.05	3.75
Finance Costs	0.00	0.00	0.01	0.00
Depreciation and amortisation expenses	0.09	0.19	0.12	0.56
Other Expenses	0.59	8.86	3.97	14.84
<b>Total Expenses (IV)</b>	<b>1.58</b>	<b>9.95</b>	<b>5.15</b>	<b>19.15</b>
<b>V. Profit/(Loss) before exceptional items and tax (III- IV)</b>	<b>-1.58</b>	<b>-7.89</b>	<b>-5.15</b>	<b>-17.09</b>
VI. Exceptional items	0.00	0.00	0.00	0.00
<b>VII. Profit/(Loss) before tax (V-VI)</b>	<b>-1.58</b>	<b>-7.89</b>	<b>-5.15</b>	<b>-17.09</b>
<b>VIII. Tax Expense</b>				
(1) Current tax	0.00	0.00	0.00	0.00
(2) Deferred tax	0.00	0.00	0.00	0.00
(3) Previous Year Tax	0.00	0.00	0.00	0.00
<b>IX. Profit/(Loss) for the period from continuing operations (VII-VIII)</b>	<b>-1.58</b>	<b>-7.89</b>	<b>-5.15</b>	<b>-17.09</b>
<b>X. Profit/(Loss) from discontinued operations</b>				0.00
XI. Tax expense of discontinued operations	0.00	0.00	0.00	0.00
<b>XII. Profit/(Loss) from Discontinued operations (after tax) (X-XI)</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>
<b>XIII. Profit/(Loss) for the period (IX+XII)</b>	<b>-1.58</b>	<b>-7.89</b>	<b>-5.15</b>	<b>-17.09</b>
<b>XIV. Other Comprehensive Income</b>		0.00		0.00
<b>(A) (i) Items that will not be reclassified to profit or loss</b>	0.00	0.00	0.00	0.00
(ii) Income tax relating to items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00
<b>(B) (i) Items that will be classified to profit or loss</b>	0.00	0.00	0.00	0.00
(ii) Income tax relating to items that will be reclassified to profit or loss	0.00	0.00	0.00	0.00
<b>XV. Total Comprehensive Income for the period (XIII+XIV)</b>	<b>-1.58</b>	<b>-7.89</b>	<b>-5.15</b>	<b>-17.09</b>
(Comprising Profit (Loss) and Other Comprehensive Income for the Period)				
<b>XVI. Paid up Equity Share Capital (Face Value of Rs. 10 Each)</b>	427.35	427.35	427.35	427.35
<b>XVII. Other Equity</b>				-657.94
<b>XVIII. Earnings per equity share (for continuing operation):</b>				
(1) Basic	-0.0370	-0.1847	-0.1204	-0.0400
(2) Diluted	-0.0370	-0.1847	-0.1204	-0.0400
<b>XIX. Earnings per equity share (for discontinued operation):</b>				
(1) Basic	0.000	0.000	0.000	0.000
(2) Diluted	0.000	0.000	0.000	0.000
<b>XX. Earnings per equity share (for discontinued &amp; continuing operations)</b>				
(1) Basic	-0.0370	-0.1847	-0.1204	-0.0400
(2) Diluted	-0.0370	-0.1847	-0.1204	-0.0400

**Notes:**

- (1) The above results have been reviewed by Audit Committee and taken on record by the Board of Directors at its Meeting held on 02.08.2023. The Statutory Auditors have carried out their audit for the above results.
- (2) The above result results are prepared in accordance with Indian Accounting Standards ("Ind AS"), the provisions of the Companies Act, 2013 ("the Act"), as applicable and guidelines issued by the Securities and Exchange Board of India ("SEBI"). The Ind AS are prescribed under Section 133 of the Act read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and Companies (Indian Accounting Standards) Amendment Rules, 2016.
- (3) The IND AS compliant corresponding figures for the period as reported above have not been subjected to review. However, the Company's management has exercised necessary due diligence to ensure that such financial results provide a true and fair view of its affairs.
- (4) The figures for the previous period/year have been regrouped/reclassified, wherever necessary, to conform to the current period/year classification
- (5) As the Company's business activity falls within a single segment, therefore "Segment Reporting" are not applicable.

**For Raymed Labs Limited**

**Ajai Goyal**  
**Director**  
**DIN : 02636418**

**Date: 02.08.2023**  
**Place : Noida**